Search

Pharma

Value

To be able to find the right path for the introduction of a medicine in Italy, it is necessary to explore and translate the map of the regulatory environment, identifying and analysing the expectations and reports of decision-makers.

We assist those who turn to us in understanding and obtaining a fair price and reimbursement for a medicine. Finding a common ground, by appropriately mediating between Company profit, patient needs and the limited resources of the National Health Service, is a victory for all interest groups involved.
Through the years, we have learnt that the reality of things is more complex than whatever had been planned.
Even when everything is well-prepared and strategies corresponding to the value of the medicine, in accordance with the regulatory objectives of the agencies, and accommodating to drug governance guidelines, are proposed, the pathway to the authorisation of a medicine may well progress differently than expected. Not to mention any external variables that could slow down, if not hinder, the access of a medicine to the market.
Integrated skills are needed to help with navigation
Though quite detailed, the map we have provided cannot define the complexity of the terrain. Our experience comes to the aid when it is not clear.
  • All
  • Scenario analysis
  • Notes
  • Drug Policy
  • Rare Diseases
  • Mapping
  • Team Pharma Value
All
  • All
  • Scenario analysis
  • Notes
  • Drug Policy
  • Rare Diseases
  • Mapping
  • Team Pharma Value
Notes

8th Orphan Drug Day - The Orphan Drug Comparator - Limits and the right to the best treatment

Rome, 16 October 2024 - In the context of rare diseases, orphan drugs play a key role because they treat conditions for which there are ...
Notes

AIFA administrative sanctions

Clarification of AIFA Administrative Sanctions The law recognises that AIFA - as the drug regulatory authority - has the power to impose administrative sanctions ...
Special HTA Regulation Scenario analysis

Pharma Value Special: The new HTA Regulation

Special European HTA Regulation The new European Regulation on Health Technology Assessment (HTA-r) 2021/2282, which comes into force on 12 January 2025, marks the ...
GIRF Bologna Notes

Pharma Value at the 3rd GIRF Congress - ISPOR Group Rome for Future

On 19 and 20 June, the 3rd National Congress of the Ispor Roma for Future GIRF group was held in Bologna, confirming ...
Aifa Guidelines - Pharma Value comments Scenario analysis

Technical Table for the revision of AIFA Notes and Therapeutic Plans

Update 17 June 2024 Below are the appointments updated to 17 June 2024. On the AIFA website you can read the new determination ...
Drug Policy

New AIFA special: CSE and reorganisation

The series of Nomos and Pharma Value specials regarding the governance of the Medicine and its Agency continues. After the seven extensions ...
Notes

LEA 2024 Commission

The National Commission for Updating the Essential Levels of Care (LEA) was renewed by Ministerial Decree of 18/03/2024. The President of the Commission ...
Notes

Happy Easter from #TeamPharmaValue

Our Easter greeting this year is multi-voiced. Each person in the team wanted to share their thoughts on Easter, ...
Notes

Pharma Value_1 year from SRL

A year has already passed since 17 February 2023, when, defying superstition and low immune defences, Pharma Value decided to grow, ...
Notes

Just be patient

On 14 February 2024 in Rome, at the Capranichetta Hall of the Hotel Nazionale, the presentation of 'Basta essere Pazienti', a campaign by the ...
en_GB